1 A wide panel of compounds acting on 1-adrenoceptors active either in mammalian heart or in rodent digestive tract 3 This pharmacological analysis further established that the 13-adrenoceptor is the prototype of the adipose tissue atypical P-adrenoceptor, since these receptors share a number of pharmacological properties which differ strikingly from those of P13-and 132-adrenoceptors: low affinities for conventional 13-adrenoceptor agonists and antagonists, high potencies for novel compounds active in adipose tissues, partial agonistic activites for several PI/p2-antagonists. 4 Although the pharmacological profiles of the human and murine 133-receptor were very similar, some quantitative or even qualitative differences were observed for particular compounds such as propranolol, which exhibited weak and partial agonistic effects at the human 133-receptors and antagonistic effects at the murine 13-receptors. These differences may result from key amino-acid substitutions between the human and the murine P3-receptor sequences, which may alter the binding site or signal processing. 5 Compounds active on atypical P-sites of other tissues such as heart and digestive tract were also potent on the P3-adrenoceptor expressed in Chinese hamster ovary cells, suggesting that this receptor mediates most of the atypical properties described in various tissues, and that differences in ligand effects may result from tissue-related specificities.